“Could Preventative Drug Be Effective In People With Migraine And Rebound Headache?” from Science News by Sue Robbins | Jul 8, 2024 | MigraineRead more here
“Atogepant Reduces Monthly Migraine Days In Patients With Chronic Migraine” from Neurology Advisor by Sue Robbins | Dec 10, 2023 | MigraineRead more here
“New Drug May Help Prevent Episodic Migraine In Difficult Cases” from MedicalNewsToday by Sue Robbins | Jun 7, 2023 | MigraineRead more here
“AbbVie Announces Positive Phase 3 Data for Atogepant in Migraine Prevention” from AbbVie News Center by Sue Robbins | Jul 30, 2020 | Migraine Phase 3 ADVANCE trial evaluating atogepant meets primary endpoint of statistically significant reduction from baseline in mean monthly migraine days, compared to placebo, for all doses evaluated across a 12-week treatment period – Trial also...
